China issues interim rules on adverse incident reporting and re-evaluation
This article was originally published in RAJ Devices
China’s State Food and Drug Administration has issued an interim regulation that strengthens adverse event reporting requirements for medical device manufacturers, distributors, medical institutions and end users, product technical evaluation agencies, SFDA provincial offices and other relevant agencies1,2. The new rules also introduce the first-ever device re-evaluation procedures. Though the regulation came into effect on 30 December, it is expected to be updated in the future with a more comprehensive version.
You may also be interested in...
China’s National Industry and Commerce Administration, Ministry of Health and State Food and Drug Administration have issued a new regulation that strengthens the rules on advertising of medical devices, particularly with respect to content1. The Medical Device Advertisement Evaluation and Release Standard came into effect on 20 May.